Michael Barbella, Managing Editor03.28.24
Endologix LLC has appointed Art Taylor to its Board of Directors.
Taylor has more than 30 years of experience in operational and financial executive leadership within the medical device, pharmaceutical, and high-tech industries. Taylor’s expertise extends to both publicly held companies and private, venture capital-backed firms. His sector experience is diverse, encompassing spine, electrophysiology, ophthalmology, hearing healthcare, and neurology. Taylor served as a member of the Board of Directors for several medical device firms that were subsequently acquired and is currently a board member for three early-stage companies, and Providence Medical Technology.
“We are excited to welcome Art Taylor to the Endologix Board of Directors,” Endologix President/CEO Matt Thompson, M.D., said. “Art’s wide-ranging experience in the healthcare sector adds a depth of knowledge to our board. His strategic acumen will be invaluable as we advance towards the full market release of our DETOUR System and equally crucial as we continue to grow our abdominal aortic aneurysm (AAA) business globally.”
Endologix LLC is a California-based, global medical device company developing therapies for interventional vascular disease treatment. Endologix’s therapeutic portfolio includes products designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX 2 Endovascular AAA System, ALTO Abdominal Stent Graft System, and the DETOUR System, treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm with offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, Calif.
Taylor has more than 30 years of experience in operational and financial executive leadership within the medical device, pharmaceutical, and high-tech industries. Taylor’s expertise extends to both publicly held companies and private, venture capital-backed firms. His sector experience is diverse, encompassing spine, electrophysiology, ophthalmology, hearing healthcare, and neurology. Taylor served as a member of the Board of Directors for several medical device firms that were subsequently acquired and is currently a board member for three early-stage companies, and Providence Medical Technology.
“We are excited to welcome Art Taylor to the Endologix Board of Directors,” Endologix President/CEO Matt Thompson, M.D., said. “Art’s wide-ranging experience in the healthcare sector adds a depth of knowledge to our board. His strategic acumen will be invaluable as we advance towards the full market release of our DETOUR System and equally crucial as we continue to grow our abdominal aortic aneurysm (AAA) business globally.”
Endologix LLC is a California-based, global medical device company developing therapies for interventional vascular disease treatment. Endologix’s therapeutic portfolio includes products designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX 2 Endovascular AAA System, ALTO Abdominal Stent Graft System, and the DETOUR System, treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm with offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, Calif.